Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceu… Read more
Regenerx Biopharm In (RGRX) - Total Liabilities
Latest total liabilities as of March 2023: $3.93 Million USD
Based on the latest financial reports, Regenerx Biopharm In (RGRX) has total liabilities worth $3.93 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regenerx Biopharm In - Total Liabilities Trend (2000–2022)
This chart illustrates how Regenerx Biopharm In's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Regenerx Biopharm In Competitors by Total Liabilities
The table below lists competitors of Regenerx Biopharm In ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The North American Income Trust plc
LSE:NAIT
|
UK | GBX41.74 Million |
|
AC/DC Battery Metals Inc.
V:ACDC
|
Canada | CA$13.74K |
|
Dear Cashmere Holding Company
PINK:DRCR
|
USA | $2.88 Million |
Liability Composition Analysis (2000–2022)
This chart breaks down Regenerx Biopharm In's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 21.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regenerx Biopharm In's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regenerx Biopharm In (2000–2022)
The table below shows the annual total liabilities of Regenerx Biopharm In from 2000 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $3.83 Million | +8.90% |
| 2021-12-31 | $3.51 Million | +4.12% |
| 2020-12-31 | $3.38 Million | +10.61% |
| 2019-12-31 | $3.05 Million | +22.41% |
| 2018-12-31 | $2.49 Million | -42.60% |
| 2017-12-31 | $4.34 Million | -37.32% |
| 2016-12-31 | $6.93 Million | -2.42% |
| 2015-12-31 | $7.10 Million | +166.84% |
| 2014-12-31 | $2.66 Million | +59.92% |
| 2013-12-31 | $1.66 Million | +20.58% |
| 2012-12-31 | $1.38 Million | +70.16% |
| 2011-12-31 | $811.00K | +31.44% |
| 2010-12-31 | $617.00K | -29.97% |
| 2009-12-31 | $881.00K | -33.56% |
| 2008-12-31 | $1.33 Million | -46.29% |
| 2007-12-31 | $2.47 Million | +97.52% |
| 2006-12-31 | $1.25 Million | +75.07% |
| 2005-12-31 | $714.00K | +23.10% |
| 2004-12-31 | $580.00K | +200.52% |
| 2003-12-31 | $193.00K | -18.57% |
| 2002-12-31 | $237.00K | +127.88% |
| 2001-12-31 | $104.00K | -57.55% |
| 2000-12-31 | $245.00K | -- |